Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

TIBEAY BioSciences

Request full access

First-in-class therapy for acute traumatic brain injury.

Nijmegen, NetherlandsFounded 2025Biotech & Life Sciences

About TIBEAY BioSciences

TIBEAY BioSciences B.V. is a Dutch clinical-stage biotechnology company developing therapies for acute neurological conditions. The company is focused on its lead candidate, Ronopterin, a first-in-class small molecule designed for the early treatment of moderate to severe traumatic brain injury (TBI). TBI is a leading cause of death and long-term disability worldwide, with an estimated 50 million new cases annually, yet there are no approved pharmacological therapies that specifically target its secondary injury mechanisms.

TIBEAY's therapeutic approach with Ronopterin targets the secondary damage that occurs after the initial trauma. The drug is a selective inhibitor of inducible nitric oxide synthase (iNOS), an enzyme that becomes highly expressed after a brain injury and contributes to the formation of neurotoxic radicals. By selectively inhibiting iNOS, Ronopterin aims to reduce this progressive tissue damage, improve neurological outcomes, and enhance the quality of life for patients. This biological pathway's significance was previously recognized by a Nobel Prize in Physiology or Medicine.

Founded in the Netherlands, the company is advancing Ronopterin into late-stage clinical development. In April 2026, TIBEAY Biosciences announced it had raised €35 million in a financing round led by ATHOS KG, with participation from MIG Capital, Meneldor, and Oost NL. The proceeds are intended to fund a European, multicenter Phase 3b registrational trial. This pivotal study is designed to form the basis for a future marketing authorization application with the European Medicines Agency (EMA). The funding will also support the manufacturing of clinical supplies, supply chain preparation, and other regulatory and operational activities.

Source: Dealroom company data

At a glance

Status
Operational
Employees
7
Open positions
None listed
Dealroom signal
85.6/100
Industry
Health
Sub-industry
BioTechnology
Sector
Drug Development, Neurology, Chronic Disease
Business model
Manufacturing
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VC✓Equity / VC Apr 2026 $39M $154M Oost NL - Eastern Netherlands Regional Development Agency · Meneldor · Athos · MIG Capital ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

TIBEAY BioSciences in the Nijmegen ecosystem

Live from Dealroom

The TIBEAY BioSciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • Athos
  • Oost NL - Eastern Netherlands Regional Development Agency
  • Meneldor
  • MIG Capital
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇨🇭 Switzerland50%
🇳🇱 Netherlands50%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about TIBEAY BioSciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See TIBEAY BioSciences’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.